JPM vs NMR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Nomura Holdings presents a stark contrast between attractive valuation and poor operational health, highlighted by a weak Piotroski F-Score of 2/9. While the stock trades significantly below its Graham Number ($11.50) and Intrinsic Value ($10.31), the fundamental health metrics are concerning. Strong revenue growth and a healthy dividend yield are offset by extreme leverage (Debt/Equity of 9.17) and a consistent track record of missing earnings estimates. The current price of $8.06 suggests a value play, but the lack of operational momentum warrants a neutral stance.
Compare Another Pair
Related Comparisons
JPM vs NMR: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nomura Holdings, Inc. (NMR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.